Compton Capital Management Inc. RI Sells 1,881 Shares of Pfizer Inc. (NYSE:PFE)

Compton Capital Management Inc. RI trimmed its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,396 shares of the biopharmaceutical company’s stock after selling 1,881 shares during the period. Pfizer comprises 1.4% of Compton Capital Management Inc. RI’s portfolio, making the stock its 22nd largest position. Compton Capital Management Inc. RI’s holdings in Pfizer were worth $2,118,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. RB Capital Management LLC increased its position in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its position in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares during the period. United Bank increased its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC increased its position in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp increased its position in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the period. 67.62% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE traded down $0.58 during trading on Wednesday, hitting $43.58. The company’s stock had a trading volume of 6,791,672 shares, compared to its average volume of 25,216,975. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 0.35. Pfizer Inc. has a one year low of $41.44 and a one year high of $56.32. The firm has a market cap of $244.63 billion, a PE ratio of 8.38, a P/E/G ratio of 1.10 and a beta of 0.67. The business’s 50 day simple moving average is $49.26 and its 200-day simple moving average is $47.78.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 29.81% and a return on equity of 43.95%. The business had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. During the same period last year, the firm earned $1.08 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 6.47 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 3rd. Stockholders of record on Friday, January 27th will be paid a $0.41 dividend. The ex-dividend date is Thursday, January 26th. This is a boost from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.76%. Pfizer’s dividend payout ratio is 31.54%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. UBS Group cut shares of Pfizer from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $55.00 to $47.00 in a report on Thursday, January 26th. Atlantic Securities cut their price objective on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a report on Wednesday. SVB Leerink cut their price objective on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a report on Wednesday. Wells Fargo & Company cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $54.00 to $50.00 in a report on Tuesday, January 17th. Finally, Barclays cut their price objective on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a report on Wednesday. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $52.27.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.